aTyr Pharma Inc.

135 articles with aTyr Pharma Inc.

• aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update

  11/12/2020

  Completesenrollment of ATYR1923clinical trial in patients with COVID-19 severe respiratory complications.Topline data is expected at turn of calendar year.

• aTyr Pharma Announces Publication in the Journal mAbs

  11/11/2020

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced a publication highlighting new technological advances to isolate, characterize and engineer a diverse, novel family of human antibodies with hi

• aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline

  11/10/2020

  aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced that it has identified receptor targets for two tRNA synthetases from its pipeline.

• aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2020 Financial Results - Management to host conference call and webcast on November 12th at 5:00 pm EST / 2:00 pm PST

  11/5/2020

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it will report third quarter 2020 financial results and provide a corporate update after the market close on Thursday, November 12, 2020. Conference Call and Webcast Details: Thursday, November 12th @ 5:00 p.m. EST / 2:00 p.m. PST Domestic: 844-358-9116 International

• aTyr Pharma to Participate in ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28th

  10/27/2020

  aTyr Pharma, Inc. announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will participate in a panel titled, “Immune Modulators to Ameliorate COVID-19” as part of the ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28, 2020.

• aTyr Pharma Announces Completion of Enrollment in Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications

  10/26/2020

  Trial evaluating the preliminary safety and efficacy of ATYR1923 vs placebo has exceeded enrollment.

• aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Doses First Subjects in Phase 1 Trial of ATYR1923 in JapanStudy will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in Japanese healthy volunteers

  9/15/2020

  aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyorin, a wholly owned subsidiary of Kyorin Holdings, Inc., has dosed the first subjects in a Phase 1 trial of aTyr’s lead therapeutic candidate ATYR1923.

• aTyr Pharma Announces $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC

  9/14/2020

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a Common Stock Purchase Agreement (the “Agreement”) providing for the sale of up to $20 million of common stock to Aspire Capital Fund, LLC,

• aTyr Pharma to Present at September 2020 Investor Conferences

  9/9/2020

  aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced that the company will present at two investor conferences in September.

• aTyr Pharma to Present at Life Sciences Investor Forum on September 17th

  9/2/2020

  aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a company overview at the Virtual Life Sciences Investor Forum, which is being held on Thursday, September 17.

• aTyr Pharma Announces Second Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trial ProgramsCompany to host conference call and webcast today, August 13, at 5:00 p.m. EDT / 2:00 p.m. PDT 

  8/13/2020

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced second quarter results and provided a corporate update.

• aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Proceeds to Phase 1 Trial of ATYR1923 in JapanStudy will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in healthy volunteers in Japan.

  8/11/2020

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyorin, a wholly owned subsidiary of Kyorin Holdings, Inc., has initiated clinical development in Japan for aTyr’s lead therapeutic candidate ATYR1923 (known as KRP-R120 in Japan) following the Pharmaceutical and Medical

• aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2020 Financial ResultsManagement to host conference call and webcast on August 13th at 5:00 pm EDT / 2:00 pm PDT

  8/6/2020

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report second quarter 2020 financial results and provide a corporate update after the market close on Thursday, August 13, 2020. Conference Call and Webcast Details: Thursday, August 13th @ 5:00 p.m. EDT / 2:00 p.m. PDT Domestic:  844-358-9116 Internationa

• aTyr Pharma Presents Preclinical Research Showing NRP2 Antibody Effects in Triple-Negative Breast Cancer at the 2020 AACR Virtual Annual Meeting II

  6/22/2020

  Poster details data from aTyr’s preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies may increase sensitivity to chemotherapy in triple-negative breast cancer. SAN DIEGO, June 22, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced a poster and audio presentation at the 2020 American Association for Cancer

• aTyr Pharma Highlights New Literature Implicating Neuropilin Pathway In SARS-CoV-2 Infection

  6/17/2020

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today highlighted new external research demonstrating the involvement of Neuropilin biology in SARS-CoV-2 infection.

• 

  Biopharma Update on the Novel Coronavirus: June 15

  6/15/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 15, 2020.

• aTyr Pharma Announces Dosing of First Patient in Phase 2 Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory ComplicationsTrial opens for enrollment of hospitalized patients at multiple centers throughout the U.S.

  6/15/2020

  aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced that it has dosed the first patient in a Phase 2 study evaluating its lead therapeutic candidate, ATYR1923, in COVID-19 patients with severe respiratory complications.

• aTyr Pharma to Present Poster at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II

  5/20/2020

  Poster details data from aTyr’s pre-clinical, domain specific Neuropilin-2 (NRP2) antibody program highlighting therapeutic potential in triple-negative breast cancer

• aTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trials in Pulmonary Sarcoidosis and COVID-19Company to host conference call and webcast today, May 12, at 5:00 p.m. EDT / 2:00 p.m. PDT

  5/12/2020

  aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced first quarter results and provided a corporate update.

• aTyr Pharma to Webcast Conference Call Reporting First Quarter 2020 Financial ResultsManagement to host conference call and webcast on May 12th at 5:00 pm EDT / 2:00 pm PDT

  5/6/2020

  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report first quarter 2020 financial results and provide a corporate update after the market close on Tuesday, May 12, 2020. Conference Call and Webcast Details: Tuesday, May 12th @ 5:00 p.m. EDT / 2:00 p.m. PDT Domestic:  844-358-9116 International:  209-90